订阅最新相关文献

A process is disclosed for producing polyamide 66 polymers from at least one circular atom component. The circular atom component, for instance, can comprise a fluid obtained from biomass or from an industrial waste stream, such as an industrial gas stream that would otherwise be released to the environment. Polyamide 66 polymers are produced not only containing large amounts of circular atoms but also with excellent mechanical and physical properties.

A hot melt composition comprising: a polyvinyl alcohol polymer; a tackifying resin comprising an aromatic hydrocarbon resin; and a plasticizer, wherein the plasticizer comprises a trifunctional or higher polyether polyol or a polyalkylene glycol having a hydroxyl value of 500 to 1,058.

本发明公开了一种基于环状RNA与dNLR的生物标志物组合在制备跨HLA‑B27亚型诊断或辅助诊断强直性脊柱炎试剂组合或试剂盒中的应用，属于生物医学检测技术领域，该生物标志物组合弥补现有标志物在疾病早期诊断敏感性不足的缺陷，为开发基于常规检测参数的 AS 无创诊断策略提供了新思路，同时也为circRNA与常规炎症指标的协同作用机制研究开辟了新方向。

本发明涉及功能水凝胶材料技术领域，具体涉及一种超声空化自适应润滑水凝胶及其制备方法和应用。本发明提供的超声空化自适应润滑水凝胶以N‑丙烯酰基甘氨酰胺、N‑丙烯酰基丙烯酰胺和甲基丙烯酰化壳聚糖中的至少一种为单体，以甲基丙烯酸酯化透明质酸钠、透明质酸‑聚乙二醇双接枝共聚物和甲基丙烯酰化硫酸软骨素中的至少一种为润滑剂，以过硫酸盐为氧化剂，以二硫化钼和/或MXene为还原剂，并控制各个原料的用量比，能够利用超声波非侵入性、深穿透性的特点，实现体内可控高效原位聚合，避免手术植入创伤，提高材料与组织的贴合性，适配体内复杂微环境；且各原料生物相容性高、生物安全性高。

A layered body manufacturing apparatus, including: a supply mechanism that supplies sheet-shaped metal pieces, including a sheet-shaped metal piece having a part of at least one surface to which an adhesive is applied; and an annular squeezer having a conveyance passage in which the metal pieces supplied from the supply mechanism are sequentially layered and conveyed. The squeezer includes: a first side pressure application region that is positioned at an end portion at a side upstream in a conveying direction of the metal pieces and that pressurizes and supports at least a part of a side surface of each of the metal pieces supplied from the supply mechanism, a second side pressure application region that is positioned at an end portion at a side downstream in the conveying direction and that pressurizes and supports the at least a part of a side surface of each of the metal pieces.

本发明公开了筛选引物组合中形成二级结构的引物的方法，包括：分别计算引物组合中每一条引物自身的Tm值减去其所形成的二级结构的Tm值的差值；若差值≤设定阈值，则判定该引物在其退火温度条件下可能形成二级结构，并将其筛选出来。本发明还公开了筛选引物组合中产生非靶向扩增产物的引物的方法，包括：分别将引物组合中每一条引物与参考基因组进行序列比对并记录比对信息；根据对引物对组合方式的要求，对每一条引物寻找所有形成扩增产物的引物对；通过表征扩增产物产生可能性的指标对扩增产物计数并按产生可能性从大到小排序；根据计数的排序结果，筛选出排序在设定范围内的引物。本发明进一步涉及利用上述筛选方法来检验引物特异性的方法。

本发明公开了一种新型无卤阻燃吸塑膜及成型工艺，自上而下依次包括耐磨抗刮表层、无卤阻燃增强层、阻隔层、阻燃层、粘结层、热封吸塑层；本发明采用磷氮协效阻燃剂与膨胀型无卤阻燃剂协同作用，配合阻燃协效剂，无需依赖含卤阻燃剂，燃烧过程中无有毒有害气体及大量烟雾产生，符合环保安全要求；同时，在较低阻燃剂添加量下即可实现优异的阻燃效果，避免了高添加量导致的性能劣化。

A self-heating snowmelt composition according to one embodiment of the present disclosure may comprise 70 to 95 weight% of an organic acid salt-based snowmelt main material, 3 to 25 weight% of a bio-based auxiliary material, and the remainder of a photothermal conversion material that absorbs sunlight and converts it into thermal energy. The photothermal conversion material may be one or more selected from the group consisting of carbon black, tungsten trioxide ( WO₃ ), triiron tetroxide ( Fe₃O₄ ), carbon nanotubes (CNT) , and polypyrrole.

Provided is a process for producing a purified carbon black with a reduced content of polycyclic aromatic hydrocarbons. The process includes (a) providing a carbon black including an initial content of polycyclic aromatic hydrocarbons, (b) treating the carbon black including an initial content of polycyclic aromatic hydrocarbons with an extraction agent including carbon dioxide in a supercritical state to extract at least a portion of the polycyclic aromatic hydrocarbons from the carbon black, and (c) removing the extraction agent including the extracted polycyclic aromatic hydrocarbons from the carbon black to obtain a purified carbon black with a lower content of polycyclic aromatic hydrocarbons than the initial content of polycyclic aromatic hydrocarbons. It is furthermore provided a carbon black obtained through said production process and articles made therefrom.

[Problem] To provide a pharmaceutical composition for the diagnosis, prevention, and/or treatment of age-related cognitive decline, including pathological neurodegeneration. [Solution] A pharmaceutical composition comprising the following components: a therapeutically effective amount of one or more of the following: a CD103 inhibitor, a perforin 1 inhibitor, and an IFNγ inhibitor, wherein the CD103 inhibitor is an anti-CD103 antibody, selected from the group consisting of PE anti-human CD103 antibody derived from clone Ber-ACT8, mouse anti-human CD103 monoclonal antibody (mAb) derived from clone 2G5.1, humanized antibody of 2G5.1, OX-62, humanized antibody of OX-62, anti-mouse CD103 mAb derived from clone 2E7, humanized antibody of 2E7, and paxilin; the perforin 1 inhibitor is selected from the group consisting of diarylthiophene and GSK2126458; and the IFNγ inhibitor is selected from the group consisting of mesopram and locagramide. [Selected Figure] None